The use of radioactively labeled monoclonal antibodies to treat malignancies, e.g., breast cancers, non-Hodgkin’s lymphoma, and prostate cancer. The monoclonal antibodies selectively bind with antigens on the tumor cells and deliver a dose of cell-killing radiation directly to those cells.